Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

Patent
Millennium Pharmaceuticals Inc. | Date: 2015-04-21

The invention relates to antibody molecules which bind pSYK, and methods for using the same for diagnosis, prognosis, to select patients for treatment with a SYK-targeted therapy, or evaluate the pharmacodynamic profile of a SYK-targeted therapy.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-11-09

The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R^(1), R^(2), R^(3), R^(4), R^(5), L^(1), L^(2), m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-05-04

Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-08-29

This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.


Patent
Millennium Pharmaceuticals Inc. and Massachusetts General Hospital | Date: 2016-06-03

Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.


Patent
Millennium Pharmaceuticals Inc. and Genentech | Date: 2017-05-17

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for 47 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.


Patent
Millennium Pharmaceuticals Inc. | Date: 2017-03-01

The invention relates to antibody molecules which bind pSYK, and methods for using the same for diagnosis, prognosis, to select patients for treatment with a SYK-targeted therapy, or evaluate the pharmacodynamic profile of a SYK-targeted therapy.


Patent
Millennium Pharmaceuticals Inc. | Date: 2017-02-22

This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.


Patent
Millennium Pharmaceuticals Inc. | Date: 2017-05-31

Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula :^(Y), R^(Y1), R^(Y2) and R^(Y3) are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.


Patent
Millennium Pharmaceuticals Inc. and Sunesis Pharmaceuticals | Date: 2016-09-21

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Loading Millennium Pharmaceuticals Inc. collaborators
Loading Millennium Pharmaceuticals Inc. collaborators